Uganda is one of just ten high-burden HIV countries where the drug will be distributed through the US President’s Emergency Plan for AIDS Relief (PEPFAR). Thank you for reading Nation.Africa Show ...

A new long-acting medicine that could make preventing HIV transition might soon be even for poor countries like Uganda thanks to agreements between producers and key HIV/AIDS prevention programme ...

Cuts proposed by the Trump administration and House Republicans could drive up new HIV cases by more than 200,000 by 2030, ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Millions more people at risk of HIV in low- and middle-income countries (LMICs) will have access to a powerful new prevention option: a low-cost, generic ...

Research published in The Lancet HIV earlier this year, experts estimated that, if purchased at scale, the cost of generic lenacapavir could range from USD 35 to USD 46 per person-year. Falling to USD ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

An experimental gene therapy from Uniqure slowed the progression of Huntington’s disease by 75% after three years ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

The event will be replaced with a retrospective and fundraiser held in partnership with the William Way LGBT Community Center ...

Advocates in Minnesota first raised fears of the possibility to 5 EYEWITNESS NEWS in March, and this month, the US House ...

Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...